The overall objectives of this proposed research is to understand the functional interaction of tenascin with its cellular and extracellular receptors and the role of these interactions in neoplastic growth and more specifically the processes of tumor cell migration and angiogenesis. The applicants believe that detailed knowledge of the role and mechanisms by which tenascin functions in human neoplasms will lead to a further understanding of host/tumor interactions that are recognized as important in the development of tumor invasion, metastasis and angiogenesis. Tenascin is an extracellular matrix glycoprotein whose highly restricted and regulated expression during fetal development, wound healing, the progression to malignant cancer, and its association with angiogenesis indicate a highly specialized function during these processes. These processes involve host/tumor and cell/matrix interactions which are distinctly different from the regulated stable interactions of normal cells and their tissue matrix environment.
The specific aims are: 1) to examine tenascin structure and function in tumor cell migration and endothelial cell angiogenesis; 2) characterize a new tenascin/cellular receptor phosphatase interaction which suggests a new mechanism of matrix/cell signaling; and 3) the examination of tenascin regulation and function in a unique human tumor/mouse in vivo intravital microscopy chamber model of tumor angiogenesis.
These aims reflect the intent to move from the investigation of in vitro function on the molecular and cell level to the examination of expression and function in an in vivo model. There is significant translational research potential in the proposed tenascin studies which suggest new matrix targeted diagnostic and therapeutic approaches to the control of solid tumors such as breast, prostate, and brain (glioma) cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA052879-11
Application #
6328919
Study Section
Pathology B Study Section (PTHB)
Program Officer
Ault, Grace S
Project Start
1990-07-19
Project End
2002-11-30
Budget Start
2000-12-01
Budget End
2002-11-30
Support Year
11
Fiscal Year
2001
Total Cost
$385,844
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
941462285
City
San Diego
State
CA
Country
United States
Zip Code
92121
Borgstrom, P; Bourdon, M A; Hillan, K J et al. (1998) Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1-10
Deryugina, E I; Bourdon, M A; Reisfeld, R A et al. (1998) Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 58:3743-50
Deryugina, E I; Bourdon, M A; Luo, G X et al. (1997) Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 110 ( Pt 19):2473-82
Deryugina, E I; Luo, G X; Reisfeld, R A et al. (1997) Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17:3201-10
Schwabe, M; Deryugina, E I; Bosco, M C et al. (1996) IL-6 signals inhibition of cell adhesion in melanoma A375-C6. Anticancer Res 16:3363-70
Deryugina, E I; Bourdon, M A (1996) Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109 ( Pt 3):643-52
Deryugina, E I; Strongin, A; Yu, C et al. (1996) A novel monoclonal antibody, L1A3, is directed to the functional site of the alpha v integrin subunit. Hybridoma 15:279-88
Deryugina, E I; Ratnikov, B I; Bourdon, M A et al. (1995) Identification of a growth factor for primary murine stroma as macrophage colony-stimulating factor. Blood 86:2568-78
Torres Filho, I P; Hartley-Asp, B; Borgstrom, P (1995) Quantitative angiogenesis in a syngeneic tumor spheroid model. Microvasc Res 49:212-26
Sriramarao, P; Mendler, M; Bourdon, M A (1993) Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci 105 ( Pt 4):1001-12

Showing the most recent 10 out of 11 publications